Ripple Neuro

Ripple Neuro owns the tools layer of the BCI pipeline. Its Grapevine and Trellis systems are already inside the labs that produce the foundational preclinical and early-human data that justifies larger clinical programs. Researchers build their experiments around these platforms, creating switching costs that compound with each new study. The company has survived and supplied the field without disclosed outside funding, suggesting real product-market fit and a lean, sustainable revenue model. As academic labs and startups alike race to publish results and launch first-in-human trials, they reach for a proven, high-channel-count recording system — and Ripple is one of the two credible suppliers. If even a fraction of the labs using Ripple hardware today graduate into clinical-stage companies, the installed base becomes a licensing or upgrade revenue stream for human-grade systems. The company is the pick-and-shovel play on the translational BCI wave, with a defensible position in the research market that could widen as more groups enter the space.

Ripple Neuro is a research tools company in a field that is consolidating around clinical endpoints. Without disclosed funding or a clear regulatory strategy, it is locked out of the high-value clinical implant market, where Blackrock Neurotech has a head start and substantially more visibility. The academic lab business is lumpy, grant-dependent, and low-margin — a handful of large studies can saturate the addressable market for research-grade recording hardware. As the BCI field shifts toward chronic, wireless, and fully-implantable systems, Ripple's benchtop-oriented products risk obsolescence. The company has not announced any recent product upgrades, regulatory milestones, or partnerships, which in a fast-moving sector signals stagnation. Competitors with deeper pockets (Blackrock, Synchron, Neuralink) are bypassing the research hardware layer entirely and building integrated clinical systems. Ripple may be stuck selling to cash-strapped PhD students while the industry moves past them.